Maximilian Mossner
Overview
Explore the profile of Maximilian Mossner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
1500
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Al Bakir I, Curtius K, Cresswell G, Grant H, Nasreddin N, Smith K, et al.
Gut
. 2025 Jan;
PMID: 39880602
Background: The risk of developing advanced neoplasia (AN; colorectal cancer and/or high-grade dysplasia) in ulcerative colitis (UC) patients with a low-grade dysplasia (LGD) lesion is variable and difficult to predict....
2.
Al Bakir I, Curtius K, Cresswell G, Grant H, Nasreddin N, Smith K, et al.
medRxiv
. 2024 Jul;
PMID: 39040198
Patients with inflammatory bowel disease (IBD) are at increased risk of colorectal cancer (CRC), and this risk increases dramatically in those who develop low-grade dysplasia (LGD). However, there is currently...
3.
Streuer A, Jann J, Boch T, Mossner M, Riabov V, Schmitt N, et al.
Ann Hematol
. 2024 Feb;
103(4):1221-1233.
PMID: 38413410
In low-risk Myelodysplastic Neoplasms (MDS), increased activity of apoptosis-promoting factors such as tumor necrosis factor (TNFα) and pro-apoptotic Fas ligand (CD95L) have been described as possible pathomechanisms leading to impaired...
4.
Lakatos E, Gunasri V, Zapata L, Househam J, Heide T, Trahearn N, et al.
bioRxiv
. 2024 Feb;
PMID: 38405882
Immune system control is a major hurdle that cancer evolution must circumvent. The relative timing and evolutionary dynamics of subclones that have escaped immune control remain incompletely characterized, and how...
5.
Coulter E, Bewicke-Copley F, Mossner M, Graham T, Fitzgibbon J, Okosun J
J Mol Diagn
. 2024 Jan;
26(4):245-256.
PMID: 38280422
Tumor relapse is well recognized to arise from treatment-resistant residual populations. Strategies enriching such populations for in-depth downstream analyses focus on tumor-specific surface markers; however, enrichment using intracellular biomarkers remains...
6.
Hockings H, Lakatos E, Huang W, Mossner M, Khan M, Metcalf S, et al.
bioRxiv
. 2023 Aug;
PMID: 37546942
Drug resistance results in poor outcomes for most patients with metastatic cancer. Adaptive Therapy (AT) proposes to address this by exploiting presumed fitness costs incurred by drug-resistant cells when drug...
7.
Househam J, Heide T, Cresswell G, Spiteri I, Kimberley C, Zapata L, et al.
Nature
. 2022 Oct;
611(7937):744-753.
PMID: 36289336
Genetic and epigenetic variation, together with transcriptional plasticity, contribute to intratumour heterogeneity. The interplay of these biological processes and their respective contributions to tumour evolution remain unknown. Here we show...
8.
Heide T, Househam J, Cresswell G, Spiteri I, Lynn C, Mossner M, et al.
Nature
. 2022 Oct;
611(7937):733-743.
PMID: 36289335
Colorectal malignancies are a leading cause of cancer-related deathand have undergone extensive genomic study. However, DNA mutations alone do not fully explain malignant transformation. Here we investigate the co-evolution of...
9.
Jann J, Mossner M, Riabov V, Altrock E, Schmitt N, Flach J, et al.
Nat Commun
. 2021 Oct;
12(1):6170.
PMID: 34697318
The bone marrow (BM) stroma in myeloid neoplasms is altered and it is hypothesized that this cell compartment may also harbor clonal somatically acquired mutations. By exome sequencing of in...
10.
Lakatos E, Hockings H, Mossner M, Huang W, Lockley M, Graham T
iScience
. 2021 Aug;
24(8):102889.
PMID: 34401670
Cell-free DNA (cfDNA) measured via liquid biopsies provides a way for minimally invasive monitoring of tumor evolutionary dynamics during therapy. Here we present liquidCNA, a method to track subclonal evolution...